InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases. The company focuses in developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which with symptoms present from birth is Spondyloepiphyseal Dysplasia congenita (SEDc). InnoSkel is led by Elvire Gouze, an experienced scientist, serial entrepreneur and expert in skeletal disorders.
Biotechnology, Therapeutics, health care
Between €10 million-€25 million

Articles about Innoskel:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Innoskel? We’re happy to assist you with our Startup Sourcing service.